How technology and healthcare are reshaping medical devices in 2026
The convergence now centers on safe, connected care
The most visible meeting point between technology and healthcare is now inside medical devices and the data systems that support them. In 2026, the main shift is not simply that hospitals use more software. Diagnostic tools, monitoring devices, imaging systems, clinical decision support, and patient-facing applications increasingly depend on data quality, connectivity, cybersecurity, and continuous performance monitoring. For readers following healthcare technology, the practical question is clear: how can digital tools improve care without adding avoidable safety, privacy, or workflow risk? Recent activity from the FDA, ONC, and WHO points in the same direction. Innovation is encouraged, but connected devices must be secure, interoperable, and understandable enough to be trusted in routine care.
What technology and healthcare means for medical devices
The phrase technology and healthcare can sound broad. In medical devices, it usually refers to four overlapping capabilities. First, software is becoming part of the device itself, whether as embedded code, Software as a Medical Device, or AI-enabled functionality. Second, devices increasingly exchange information with electronic health records, imaging systems, cloud platforms, patient portals, and mobile applications. Third, more care activities are moving beyond traditional clinical settings through remote monitoring and patient-facing tools. Fourth, device safety now includes cybersecurity and data governance, not only mechanical reliability or electrical performance.
This changes how value is judged. A connected device is not useful only because it captures a signal. It must capture the right signal, place it in the right clinical context, protect it from misuse, and make it available to the right person at the right time. That is why digital health strategy now sits close to regulatory affairs, quality management, clinical operations, IT security, and patient safety.
Key policy markers shaping the market
Several recent policy markers help explain why 2026 is an important year for healthcare technology. They do not all apply to every company or device, but together they show the direction of travel for the market.
| Date | Policy or source | Why it matters |
|---|---|---|
| December 29, 2022 | U.S. Consolidated Appropriations Act, 2023 | Added section 524B to the Federal Food, Drug, and Cosmetic Act, creating cybersecurity submission requirements for many connected cyber devices. |
| March 29, 2023 | FDA cybersecurity implementation date | Premarket submissions for covered cyber devices began needing cybersecurity information, including vulnerability management planning and a software bill of materials. |
| March 11, 2024 | ONC HTI-1 effective date | Updated U.S. health IT certification rules, including algorithm transparency and information-sharing provisions. |
| May 23, 2025 | World Health Assembly decision | Extended the WHO Global Strategy on Digital Health timeline to 2027 and set work toward a 2028-2033 strategy. |
| June 27, 2025 | FDA final cybersecurity guidance update | Updated FDA recommendations on cybersecurity quality system considerations and premarket submission content for devices with cybersecurity risk. |
| January 1, 2026 | ONC USCDI v3 baseline | USCDI Version 3 became the new baseline standard in the ONC Health IT Certification Program. |
| August 18, 2026 | FDA generative AI medical device discussion paper | Opened public discussion on risk assessment, premarket evaluation, and postmarket monitoring for generative AI-enabled medical devices, with feedback requested by October 19, 2026. |
The pattern is that digital capability is being tied to accountability. Regulators are asking not only whether a device works at launch, but also how it behaves after deployment, how users understand it, how it is updated, and how risks are controlled across the product life cycle.
Where connected devices are changing care
AI-enabled diagnostics and decision support
AI-enabled medical devices are one of the clearest examples of the convergence between technology and healthcare. The FDA maintains a public list of AI-enabled medical devices authorized for marketing in the United States, and its 2026 entries show continued activity across areas such as radiology and cardiovascular care. The FDA does not describe the list as a complete inventory of every possible AI device, but it is useful evidence that AI has moved beyond pilots and into regulated device pathways.
The next issue is not whether AI will be used, but how it should be evaluated. The FDA’s August 2026 discussion paper on generative AI-enabled medical devices highlights risk assessment, premarket evaluation, and postmarket monitoring as open questions. Generative systems can produce variable outputs, which makes them different from traditional deterministic software. For device developers, documentation may need to explain intended use, model behavior, output limits, human oversight, update controls, and real-world performance monitoring.
Interoperability and clinical context
Devices become more valuable when their data can move safely and meaningfully. A bedside monitor, imaging system, implantable sensor, or home diagnostic tool may generate clinically useful data, but that data has limited value if it remains isolated. ONC’s HTI-1 final rule is relevant because it connects certified health IT to transparency, information sharing, and data standards. ONC states that certified health IT supports care delivered by more than 96% of hospitals and 78% of office-based physicians in the United States, which makes certification policy highly relevant to device data workflows.
USCDI v3 becoming the baseline for the ONC Health IT Certification Program on January 1, 2026 matters because medical device data increasingly needs to fit into broader patient records. Better interoperability does not automatically solve clinical workload problems, but it can reduce duplicate entry, improve continuity of care, and make device-generated information more usable for clinicians and patients.
Cybersecurity as a patient safety issue
Connected healthcare also expands the attack surface. FDA cybersecurity materials emphasize that internet-connected devices, hospital networks, and related systems can improve care, but they can also create cybersecurity risks that may affect safety and effectiveness. Under section 524B, many premarket submissions for covered cyber devices must include information such as a plan to monitor and address postmarket vulnerabilities, processes to maintain reasonable assurance of cybersecurity, and a software bill of materials covering commercial, open-source, and off-the-shelf components.
This is a major change in mindset. Cybersecurity can no longer be treated as an IT checklist added after product design. It has to be considered during architecture, supplier selection, software development, risk management, labeling, update strategy, incident response, and postmarket surveillance. For health systems, the same principle applies operationally: a secure device depends on coordinated work between manufacturers, hospitals, facilities teams, and clinical users.
Remote monitoring and patient-facing software
Remote monitoring and patient-facing software are also changing expectations. Patients are increasingly involved in generating and viewing health information outside the clinic. This can support chronic disease management, recovery monitoring, and earlier detection of deterioration. The device still has to fit the patient context. Connectivity, battery life, usability, alert design, language accessibility, and data accuracy can determine whether a digital health tool reduces friction or creates new burdens.
The practical lesson is that patient-facing technology should be designed around the full care pathway. A measurement is only useful if someone knows what to do with it. Alerts need thresholds and escalation plans. Clinicians need workflows that separate urgent signals from noise. Patients need clear instructions and realistic expectations about what the device can and cannot tell them.
What this means for manufacturers and care teams
For manufacturers, the convergence of technology and healthcare changes product planning. Regulatory strategy now needs to start earlier, especially for devices that include AI, cloud connectivity, mobile interfaces, cybersecurity exposure, or integration with certified health IT. Development teams should define intended use carefully, document data provenance, validate performance in the right population, plan software updates, and prepare postmarket monitoring before launch.
For care teams and health systems, procurement questions are changing as well. Traditional device evaluation focused on clinical performance, cost, training, service, and compatibility. Those points still matter, but digital products add new questions:
- Does the device integrate with existing EHR, imaging, or monitoring infrastructure?
- What data standards and interfaces are supported?
- How are software updates tested, communicated, and deployed?
- What cybersecurity documentation, SBOM information, and vulnerability disclosure process are available?
- How does the product perform across patient groups, settings, and user skill levels?
- What happens if connectivity fails or model performance changes over time?
These questions are not barriers to adoption. They are the conditions for sustainable adoption. Technology that is clinically useful but hard to govern may create hidden costs. Technology that is secure but poorly integrated may be ignored. Technology that is accurate in testing but confusing in real workflows may fail to improve care. See also: clinical equipment.
Risks and limits to watch
The main risk is overconfidence. A device can be FDA-authorized and still require local validation, user training, workflow design, and ongoing monitoring. Authorization means the device met applicable premarket requirements for its intended use; it does not mean every hospital environment, patient population, or operational workflow will produce the same result.
Another risk is data bias or incomplete performance reporting. AI-enabled tools may perform differently across populations, care settings, scanner types, input quality, or disease prevalence. Interoperability can also introduce ambiguity if data elements are mapped incorrectly or stripped of context. Cybersecurity controls can fail if software components are poorly tracked or if updates are delayed. Patient-facing tools may widen access for some groups while excluding others because of language, broadband, disability, or digital literacy barriers.
Good governance does not eliminate these problems, but it makes them visible. A mature approach includes clinical validation, human factors testing, cybersecurity risk management, data quality review, change control, monitoring for drift, and clear responsibility when device output conflicts with clinical judgment.
What to watch next
Three developments are worth watching after August 2026. First, the FDA’s generative AI discussion process may shape future expectations for devices that produce narrative, multimodal, or adaptive outputs. Because the paper is discussion-oriented and not final guidance, it should be read as a signal of regulatory questions rather than a binding rule.
Second, interoperability policy will keep affecting medical device strategy as more device data flows into certified health IT environments. USCDI v3 is not just a technical milestone; it reflects the push toward more complete, usable, and standardized patient information.
Third, cybersecurity will remain a product life cycle issue. FDA’s 2025 final guidance update and section 524B requirements show that regulators expect manufacturers to plan for vulnerabilities, patches, and software component transparency before devices reach the market.
The broader conclusion is straightforward: healthcare technology is moving from isolated digital features toward connected, regulated, and continuously monitored systems. Medical device organizations that treat software, data, security, and workflow as core design elements will be better positioned than those that treat them as add-ons.
Frequently asked questions
What is the relationship between technology and healthcare in medical devices?
In medical devices, the relationship is the use of software, data, connectivity, automation, and digital interfaces to support diagnosis, monitoring, treatment, and care coordination. The key point is that these technologies must be evaluated for safety, performance, usability, cybersecurity, and clinical workflow impact.
Are AI-enabled medical devices already used in healthcare?
Yes. The FDA maintains a public list of AI-enabled medical devices authorized for marketing in the United States, and entries continued to appear in 2026. Many are associated with imaging and other data-rich specialties, although AI use is expanding into broader clinical software and decision support areas.
Why is cybersecurity now part of medical device safety?
Many devices connect to networks, cloud systems, other devices, or clinical platforms. If a vulnerability affects device availability, data integrity, or device control, it can become a patient safety issue. That is why U.S. requirements for covered cyber devices include vulnerability management planning, secure development processes, postmarket patching, and software bill of materials information.
Does interoperability matter for device performance?
Interoperability does not replace device accuracy, but it affects whether device data can be used in care. A reliable measurement may still have limited value if it cannot reach the record, the clinician, or the patient in a usable form. Standards-based exchange helps turn device output into actionable clinical information.
What should buyers ask before adopting connected healthcare technology?
Buyers should ask how the device is validated, how it integrates with existing systems, how updates are controlled, what cybersecurity documentation is available, how alerts affect workflow, and how performance will be monitored after deployment. The strongest products usually come with both clinical evidence and operational clarity.
